Postmenopausal Serum Sex Steroids and Risk of Hormone Receptor-Positive and -Negative Breast Cancer: a Nested Case-Control Study
Postmenopausal Serum Sex Steroids and Risk of Hormone Receptor-Positive and -Negative Breast Cancer: a Nested Case-Control Study
复制标题
DOI：
10.1158/1940-6207.capr-11-0090
复制
发表时间：
2011-10-01
影响因子：
3.3
通讯作者：
Kaaks, Rudolf
中科院分区：
文献类型：
--
作者：
James, Rebecca E.;Lukanova, Annekatrin;Kaaks, Rudolf
诊断前内源性类固醇激素水平与乳腺癌的总体风险存在明确的关联。尽管越来越多的证据表明存在不同的乳腺癌亚型，但很少有研究调查性类固醇激素水平与激素受体[雌激素受体（ER）和/或孕激素受体（PR）]定义的乳腺癌风险之间的关系。在 EPIC 队列（欧洲癌症与营养前瞻性调查）的一项病例对照研究中，对献血时未使用激素替代疗法的绝经后妇女的诊断前血清样本中的雌二醇、睾酮和性激素结合球蛋白水平进行了测量。共有 554 名患有浸润性乳腺癌且具有受体状态信息的女性与 821 名对照受试者进行了匹配。条件逻辑回归模型根据肿瘤的激素受体状态用激素浓度估计乳腺癌风险。性类固醇激素不仅与 ER+PR+ 乳腺癌风险相关[最高与最低三分位数的雌二醇 OR = 2.91 (95% CI: 1.62-5.23)，P 趋势 0.002；睾酮 OR = 2.27 (95% CI: 1.35-3.81)，P-趋势 0.002] 但也适用于 ER-PR-乳腺癌 [雌二醇 OR = 2.11 (95% CI: 1.00-4.46)，P-趋势 = 0.05；睾酮 OR = 2.06（95% CI：0.95-4.46），P 趋势 = 0.03]，在受体阳性疾病中关联性似乎更强。血清雄激素和雌激素与激素受体阴性和受体阳性乳腺肿瘤的风险相关。需要进一步的研究来确定雄激素和雌激素通过哪些分子途径以及在发育的哪个进化阶段可以促进受体阳性和阴性临床乳腺肿瘤的发生。癌症预防研究； 4（10）； 1626-35。 (C)2011 AACR。
Prediagnostic endogenous sex steroid hormone levels have well established associations with overall risk of breast cancer. While evidence toward the existence of distinct subtypes of breast cancer accumulates, few studies have investigated the associations of sex steroid hormone levels with risk of hormone receptor [estrogen receptor (ER) and/or progesterone receptor (PR)] defined breast cancer. In a case-control study nested within the EPIC cohort (European Prospective Investigation into Cancer and Nutrition), estradiol, testosterone, and sex hormone-binding globulin levels were measured in prediagnostic serum samples from postmenopausal women not using hormone replacement therapy at blood donation. A total of 554 women who developed invasive breast cancer with information on receptor status were matched with 821 control subjects. Conditional logistic regression models estimated breast cancer risk with hormone concentrations according to hormone receptor status of the tumor. Sex steroid hormones were associated with risks of not only ER+PR+ breast cancer [estradiol OR for highest vs. lowest tertile = 2.91 (95% CI: 1.62-5.23), P-trend 0.002; testosterone OR = 2.27 (95% CI: 1.35-3.81), P-trend 0.002] but also of ER-PR- breast cancer [estradiol OR = 2.11 (95% CI: 1.00-4.46), P-trend = 0.05; testosterone OR = 2.06 (95% CI: 0.95-4.46), P-trend = 0.03], with associations appearing somewhat stronger in the receptor-positive disease. Serum androgens and estrogens are associated with risks of both hormone receptor-negative as well as receptor-positive breast tumors. Further research is needed to establish through which molecular pathways, and during which evolutionary stages of development, androgens and estrogens can promote the occurrence of both receptor-positive and -negative clinical breast tumors. Cancer Prev Res; 4(10); 1626-35. (C)2011 AACR.